To establish an eligibility exception for the drug discount program due to cuts to the Medicaid program.

On August 20, 2026, Rep. Hillary Scholten (D-MI-3) introduced HR10134, titled 'To establish an eligibility exception for the drug discount program due to cuts to the Medicaid program.' The bill was referred to the House Committee on Energy and Commerce. It has no cosponsors and only three actions (introduction and referral). The bill's title suggests it modifies the 340B drug discount program, which requires drug manufacturers to provide discounts to covered entities serving low-income patients. The phrase 'due to cuts to the Medicaid program' implies the bill creates an exception for entities affected by Medicaid reductions. However, no bill text is available, and the legislative process is at its earliest stage. The 340B program affects pharmaceutical manufacturers (e.g., $LLY, $JNJ) and covered entities (e.g., hospitals like $HCA, $THC), but without specific language, no direct revenue impact can be estimated. The bill lacks momentum: a single sponsor, no cosponsors, and only a committee referral. The next step would be committee hearings or markup, which have not been scheduled. Given the procedural status, there is no actionable market signal. Investors should monitor for committee action or a released bill text before assessing potential impacts on drug pricing or hospital margins.